Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
In summary, besides steroids, current treatments focus on amplification (hearing aids/CI), oxygen therapy, and behavioral/neuromodulatory methods, but many patients still have persistent deficits or tinnitus
Despite the failed clinical program, AOD-9604 is widely sold as a research chemical and discussed in biohacking communities as a fat-loss agent
The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners
This origin has a profound practical consequence: unlike nearly all other research peptides, the BPC-157 peptide is resistant to hydrolysis and enzymatic degradation in gastric conditions
